Losartan Potassium

A to Z Drug Facts

Losartan Potassium

  Action
  Indications
  Contraindications
  Route/Dosage
  Interactions
  Lab Test Interferences
  Adverse Reactions
  Precautions
Patient Care Considerations
  Administration/Storage
  Assessment/Interventions
  Patient/Family Education


(low-SAHR-tan poe-TASS-ee-uhm)
Cozaar
Tablets: 25 mg
Tablets: 50 mg
Tablets: 100 mg
Class: Antihypertensive, Angiotensin II antagonist

  Action Antagonizes the effect of angiotension II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

  Indications

Treatment of hypertension; nephropathy in type 2 diabetic patients.

  Contraindications Standard considerations.

  Route/Dosage

Hypertension

Adults: PO Initial dose: 50 mg once/day; 25 mg once/day if volume depleted or history of hepatic impairment. Maintenance: 25 to 100 mg/day.

Nephropathy in Type 2 Diabetes

Adults: PO Initial dose: 50 mg once daily; the dose may be increased to 100 mg once daily based on BP response.

  Interactions

Lithium

Plasma concentrations may be increased by losartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

  Lab Test Interferences None well documented.

  Adverse Reactions

CNS: Dizziness; insomnia. EENT: Nasal congestion. GI: Diarrhea; dyspepsia. RESPIRATORY: Cough; sinusitis. OTHER: Muscle cramps; myalgia; back pain; leg pain.

  Precautions

Pregnancy: Category D (second and third trimester); Category C (first trimester). Can cause injury or death to fetus if used during second or third trimester. Lactation: Undetermined. Children: Safety and efficacy in children younger than 18 yr not established. Renal function impairment: Use caution in treating patients whose renal function may depend on the activity of the renin-angiotension-aldosterone system (eg, patients with severe CHF). Hepatic function impairment: Losartan total plasma clearance is lower (50%) and total bioavailability is higher (2-fold) in patients with hepatic insufficiency as compared with healthy subjects. A lower initial dose is recommended for patients with a history of hepatic impairment. Hypotension/Volume-depleted patients: Symptomatic hypotension may occur after initiation of losartan in patients who are intravascularly volume depleted (eg, those treated with diuretics). Correct these conditions prior to administration of losartan or use a lower starting dose. African-Americans: Losartan may not be as effective in African-Americans.


PATIENT CARE CONSIDERATIONS


  Administration/Storage

  Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
 Hypotension, tachycardia

  Patient/Family Education

Books@Ovid
Copyright
© 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts